Results 181 to 190 of about 334,676 (308)

Machine‐Learning Microfluidic Minute‐Scale Microorganism Metrics Monitoring(M6)

open access: yesAdvanced Science, EarlyView.
ABSTRACT On‐site monitoring of microorganisms remains challenging because of low concentrations, strong background interference, and dynamic aerosol diffusion, particularly for aerosol‐transmitted pathogens. Here, we report a rapid detection platform that integrates a Puri‐focusing microfluidic chip, electrochemical impedance spectroscopy (EIS), and ...
Ning Yang   +14 more
wiley   +1 more source

Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors. [PDF]

open access: yesViruses
Choudhuri I   +5 more
europepmc   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou   +12 more
wiley   +1 more source

UCHL3 Regulates Subgenomic Flaviviral RNA Condensates to Promote Virus Propagation

open access: yesAdvanced Science, EarlyView.
ABSTRACT Flavivirus subgenomic RNAs (sfRNAs) antagonise antiviral defences, yet how sfRNAs are organized and maintained in cells remains poorly understood. Here we identify ubiquitin C‐terminal hydrolase L3 (UCHL3) as a post‐translational regulator of flavivirus sfRNA stability and function.
Oscar Trejo‐Cerro   +7 more
wiley   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen   +13 more
wiley   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu   +4 more
wiley   +1 more source

A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage. [PDF]

open access: yesJ Infect Dis
Moeser MJ   +21 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy